{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:28:51Z","timestamp":1773286131065,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.4158\/ep13159.or","type":"journal-article","created":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T22:40:01Z","timestamp":1378507201000},"page":"52-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Real-World Insulin Treatment Persistence among Patients with Type 2 Diabetes"],"prefix":"10.1016","volume":"20","author":[{"given":"Wenhui","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunshen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"Baser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP13159.OR_bb0005","first-page":"130","article-title":"Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature","volume":"12","author":"Stephens","year":"2006","journal-title":"J Manag Care Pharm."},{"key":"10.4158\/EP13159.OR_bb0010","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/archinte.166.17.1836","article-title":"Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP13159.OR_bb0015","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.2337\/diacare.27.12.2800","article-title":"Clinical outcomes and adherence to medications measured by claims data in patients with diabetes","volume":"27","author":"Pladevall","year":"2004","journal-title":"Diabetes Care."},{"key":"10.4158\/EP13159.OR_bb0020","first-page":"31","article-title":"Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review","volume":"19","author":"Lee","year":"2006","journal-title":"Manag Care Interface."},{"key":"10.4158\/EP13159.OR_bb0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3111\/13696990903479199","article-title":"Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper","volume":"13","author":"Breitscheidel","year":"2010","journal-title":"J Med Econ."},{"key":"10.4158\/EP13159.OR_bb0030","first-page":"144","article-title":"Costs and utilization associated with pharmaceutical adherence in a diabetic population","volume":"10","author":"Hepke","year":"2004","journal-title":"Am J Manag Care."},{"key":"10.4158\/EP13159.OR_bb0035","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.mlr.0000163641.86870.af","article-title":"Impact of medication adherence on hospitalization risk and healthcare cost","volume":"43","author":"Sokol","year":"2005","journal-title":"Medical Care."},{"key":"10.4158\/EP13159.OR_bb0040","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1377\/hlthaff.2011.1198","article-title":"Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually","volume":"31","author":"Jha","year":"2012","journal-title":"Health Aff (Millwood)."},{"key":"10.4158\/EP13159.OR_bb0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.amjmed.2008.09.030","article-title":"From randomized controlled trials to observational studies","volume":"122","author":"Silverman","year":"2009","journal-title":"Am J Med."},{"key":"10.4158\/EP13159.OR_bb0050","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2337\/diaclin.30.2.54","article-title":"A perspective on principles of comparative cost-effectiveness studies for pharmacotherapy of chronic diseases","volume":"30","author":"Farahani","year":"2012","journal-title":"Clin Diabetes."},{"key":"10.4158\/EP13159.OR_bb0055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health."},{"key":"10.4158\/EP13159.OR_bb0060","doi-asserted-by":"crossref","first-page":"845","DOI":"10.4158\/EP10401.OR","article-title":"Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting","volume":"17","author":"Davis","year":"2011","journal-title":"Endocr Pract."},{"key":"10.4158\/EP13159.OR_bb0065","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3111\/13696998.2011.605818","article-title":"Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID","volume":"14","author":"Baser","year":"2011","journal-title":"J Med Econ."},{"key":"10.4158\/EP13159.OR_bb0070","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s12325-011-0074-5","article-title":"A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens","volume":"28","author":"Xie","year":"2011","journal-title":"Adv Ther."},{"key":"10.4158\/EP13159.OR_bb0075","series-title":"International Classification of Diseases, 9th Revision, Clinical Modification","author":"Buck","year":"2011"},{"key":"10.4158\/EP13159.OR_bb0080","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol."},{"key":"10.4158\/EP13159.OR_bb0085","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1185\/03007995.2012.654850","article-title":"Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes","volume":"28","author":"Levin","year":"2012","journal-title":"Curr Med Res Opin."},{"key":"10.4158\/EP13159.OR_bb0090","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1089\/dia.2012.0253","article-title":"Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus","volume":"15","author":"Xie","year":"2013","journal-title":"Diabetes Technol Ther."},{"key":"10.4158\/EP13159.OR_bb0095","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/dc11-2048","article-title":"Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes","volume":"35","author":"Zhao","year":"2012","journal-title":"Diabetes Care."},{"key":"10.4158\/EP13159.OR_bb0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika."},{"key":"10.4158\/EP13159.OR_bb0105","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc12-s011","article-title":"Standards of medical care in diabetes\u20142012","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care."},{"issue":"Suppl 1","key":"10.4158\/EP13159.OR_bb0110","first-page":"A244","article-title":"Treatment patterns and A1C reduction after adding a 3rd agent to 2 oral antidiabetic drugs","volume":"61","author":"Xie","year":"2012","journal-title":"Diabetes."},{"key":"10.4158\/EP13159.OR_bb0115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1185\/03007990903421994","article-title":"Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization","volume":"26","author":"Cooke","year":"2010","journal-title":"Curr Med Res Opin."},{"key":"10.4158\/EP13159.OR_bb0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6823-11-3","article-title":"Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis","volume":"11","author":"Bonafede","year":"2011","journal-title":"BMC Endocr Disord."},{"key":"10.4158\/EP13159.OR_bb0125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/dom.12083","article-title":"Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes","volume":"15","author":"Meneghini","year":"2013","journal-title":"Diabetes Obes Metab."},{"key":"10.4158\/EP13159.OR_bb0130","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1185\/03007995.2013.811403","article-title":"Real-world comparative outcomes of US yype 2 diabetes patients initiating analog basal insulin therapy","volume":"29","author":"Davis","year":"2013","journal-title":"Curr Med Res Opin."},{"key":"10.4158\/EP13159.OR_bb0135","article-title":"Insulin detemir versus insulin glargine for type 2 diabetes mellitus","volume":"6","author":"Swinnen","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"key":"10.4158\/EP13159.OR_bb0140","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/j.1742-1241.2010.02520.x","article-title":"A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study","volume":"64","author":"Gordon","year":"2010","journal-title":"Int J Clin Pract."},{"key":"10.4158\/EP13159.OR_bb0145","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1185\/03007995.2011.598500","article-title":"Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial\/syringe in insulin-na\u00efve patients with type 2 diabetes","volume":"27","author":"Buysman","year":"2011","journal-title":"Curr Med Res Opin."},{"key":"10.4158\/EP13159.OR_bb0150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/PPA.S10467","article-title":"A retrospective database analysis of insulin use patterns in insulin-na\u00efve patients with type 2 diabetes initiating basal insulin or mixtures","volume":"4","author":"Bonafede","year":"2010","journal-title":"Patient Prefer Adherence."},{"key":"10.4158\/EP13159.OR_bb0155","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MJT.0b013e3181ef4dde","article-title":"Addressing barriers to insulin therapy: the role of insulin pens","volume":"18","author":"Magwire","year":"2011","journal-title":"Am J Ther."},{"key":"10.4158\/EP13159.OR_bb0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/dia.2010.0128","article-title":"Factors associated with persistence and resumption of insulin pen use for patients with type 2 diabetes","volume":"13","author":"Peyrot","year":"2011","journal-title":"Diabetes Technol Ther."},{"key":"10.4158\/EP13159.OR_bb0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4158\/EP11097.OR","article-title":"Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus","volume":"18","author":"Levin","year":"2012","journal-title":"Endocr Pract."},{"key":"10.4158\/EP13159.OR_bb0170","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/dc09-2191","article-title":"Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study","volume":"33","author":"Arnolds","year":"2010","journal-title":"Diabetes Care."},{"key":"10.4158\/EP13159.OR_bb0175","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1185\/030079907X242638","article-title":"Barriers to the initiation of, and persistence with, insulin therapy","volume":"23","author":"Oliveria","year":"2007","journal-title":"Curr Med Res Opin."},{"key":"10.4158\/EP13159.OR_bb0180","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","article-title":"Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study","volume":"29","author":"Peyrot","year":"2012","journal-title":"Diabet Med."},{"key":"10.4158\/EP13159.OR_bb0185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/diaspect.22.2.77","article-title":"Cost-related medication underuse: a window into patients\u2019 medication-related concerns","volume":"22","author":"Piette","year":"2009","journal-title":"Diabetes Spectrum."},{"key":"10.4158\/EP13159.OR_bb0190","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/diacare.27.2.384","article-title":"Problems paying out-of-pocket medication costs among older adults with diabetes","volume":"27","author":"Piette","year":"2004","journal-title":"Diabetes Care."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20435682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20435682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/QJ6U336873K63337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:57:40Z","timestamp":1761515860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20435682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1530891X20435682"],"URL":"https:\/\/doi.org\/10.4158\/ep13159.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Insulin Treatment Persistence among Patients with Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP13159.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}